On-Q-ity, founded in 2009, was a cancer diagnostic company focused on DNA repair biomarkers and circulating tumor cell (CTC) technology. Despite raising nearly $32 million and showing early promise, the company faced technical challenges and management instability, leading to its closure by the end of 2012.
What Was On-Q-ity?
On-Q-ity developed DNA Repair biomarkers and a circulating tumor cell (CTC) platform, aiming to revolutionize cancer diagnostics. Their unique value lay in enhancing cancer treatment decisions through advanced CTC technology. Notable achievements include raising $31.97 million and securing strong intellectual property in the CTC domain.
What Happened to On-Q-ity?
The story of On-Q-ity is a compelling example of the highs and lows experienced by many startups in the biotech industry:
Initial Success and Promise: On-Q-ity was formed in 2009 through the merger of Cellective Dx and DNAR, attracting $26 million in Series A funding from four venture capital firms. The company was initially seen as promising due to its focus on DNA Repair pathway biomarkers and a circulating tumor cell (CTC) platform.
Technological Innovations: The company developed DNA Repair pathway biomarkers for predicting drug response in breast and lung cancer. Additionally, their CTC platform was validated favorably against Veridex’s approach after significant redevelopment, showcasing its potential in cancer diagnostics.
Challenges in Scaling: Early trials for DNA repair biomarkers failed to reproduce expected results, consuming over 60% of the Series A capital. The CTC platform required extensive redevelopment, which took a year and significant resources, further straining the company’s finances.
Financial Struggles and Competition: By early 2012, On-Q-ity ran out of money and had to secure a small Series B round to continue operations. Despite efforts to find a strategic partner or acquirer, the company faced financial constraints and stiff market competition, making it difficult to sustain operations.
Eventual Decline and Closure: By the end of 2012, the company was once again low on cash, leading the board to decide on an orderly wind-down. The sale of remaining intellectual property assets was completed by April 2013, marking the end of On-Q-ity’s journey.
When Did On-Q-ity Shut Down?
On-Q-ity shut down operations by the end of 2012 due to financial constraints and technical challenges. The final sale of its remaining intellectual property assets was completed in April 2013, marking the official end of the company.
Why Did On-Q-ity Shut Down?
Failed Clinical Trials: Early trials for DNA repair biomarkers did not reproduce the expected results, consuming a significant portion of the Series A capital. By mid-2010, it was clear that the biomarkers were problematic, with subsequent trials also failing, leading to a substantial financial drain.
Technological Issues: The circulating tumor cell (CTC) platform required extensive redevelopment, which took valuable time and resources. This included rebuilding antibodies and other reagents, delaying progress and straining the company's finances.
Management Instability: Frequent changes in the management team created instability and hindered progress. The company experienced a revolving door of key executives, including the CBO, CFO, CSO, CMO, COO, and CEO, which disrupted strategic continuity.
Market Timing: The market for CTCs was not mature enough to support the business model. Despite the technological advancements, the market was not ready to adopt the CTC platform, making it difficult for On-Q-ity to gain traction.
Financial Missteps: The initial large Series A round was not tranching, leading to inefficient capital allocation. This lack of phased funding meant that significant resources were committed upfront without validating the technology, resulting in financial inefficiencies.
Lessons Learned from On-Q-ity's Failure
Validate Technology Early: Ensure initial trials and validations are successful before committing significant resources to avoid financial drain and technical setbacks.
Phased Funding: Implement tranching in funding rounds to allocate capital efficiently and validate milestones before further investment.
Stable Leadership: Maintain a consistent management team to ensure strategic continuity and avoid disruptions in company progress.
Market Readiness: Assess market maturity and readiness for new technologies to ensure there is demand and support for your product.
Resource Allocation: Allocate resources judiciously, balancing between development and operational needs to avoid financial strain.
Strategic Partnerships: Seek strategic partners early to bolster financial stability and enhance market positioning.
Adaptability: Be prepared to pivot and adapt strategies in response to technological and market challenges.
We Shut Down Startups
On-Q-ity's journey underscores the complexities and challenges that startups face, often leading to difficult decisions like winding down. If you're in a similar situation, Sunset can help you navigate the legal, tax, and operational burdens seamlessly.
Don't let the stress of shutting down your startup overwhelm you. Book a demo with Sunset today to ensure a smooth and efficient wind-down process, allowing you to move on to your next venture without penalties or liabilities.
.png)
